Mutagenicity and carcinogenicity of biological reactive intermediate's derived from a "non-genotoxic" carcinogen.
Lau
S S
SS
Center for Molecular and Cellular Toxicology, Division of Pharmacology and Toxicology, College of Pharmacy, University of Texas at Austin, 78712-1074, USA.
Yoon
H S
HS
Patel
S K
SK
Everitt
J I
JI
Walker
C L
CL
Monks
T J
TJ
D000818:Animals; D002273:Carcinogens / Q000008:administration & dosage / Q000494:pharmacology*; D002292:Carcinoma, Renal Cell / Q000139:chemically induced* / Q000473:pathology; D002455:Cell Division; D002471:Cell Transformation, Neoplastic; D005978:Glutathione / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology*; D006801:Humans; D006873:Hydroquinones / Q000008:administration & dosage / Q000494:pharmacology*; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D007680:Kidney Neoplasms / Q000139:chemically induced* / Q000473:pathology; D019656:Loss of Heterozygosity; D009153:Mutagens / Q000008:administration & dosage / Q000494:pharmacology*; D012097:Repressor Proteins / Q000235:genetics; D000077005:Tuberous Sclerosis Complex 2 Protein; D025521:Tumor Suppressor Proteins
D002273:Carcinogens; D006873:Hydroquinones; D009153:Mutagens; D012097:Repressor Proteins; D000077005:Tuberous Sclerosis Complex 2 Protein; D025521:Tumor Suppressor Proteins; C078765:2,3,5-(triglutathion-S-yl)hydroquinone; D005978:Glutathione; C031927:hydroquinone